A PNRI team led by Dr. Ingegerd Hellstrom, and an Australian team, led by Dr. Bruce Robinson, of the University of Western Australia, conducted the research, which appears in the November 15th issue of Lancet. The new test promises a simple technique for diagnosing and monitoring mesothelioma early in its progress, when therapy is more likely to be successful. Fujirebio Diagnostics, Inc. (FDI) of Malvern, PA, a leading oncology diagnostic company, has acquired an exclusive license from PNRI to develop a commercial test for worldwide distribution.
According to Hellstrom, mesothelioma cells release distinctive molecular markers, SMR (soluble mesothelin-related proteins), into the blood stream. Hellstrom and her colleagues have identified this group of markers and have developed a test to detect them with great specificity.
In blood samples gathered from 273 individuals, researchers found that 84% of those with mesothelioma exhibited high levels of SMR. Only 1.9% of those with other forms of cancer or lung disease had any increased SMR, and patients who were healthy and had not been exposed to asbestos showed no biomarker increase.
"This is a very important breakthrough in the diagnosis and treatment of mesothelioma," Hellstrom explains. "Currently, no blood test exists to detect this cancer and the new biomarker will help doctors see the disease that so far has required much more complicated and expensive tests, and that even then has often gone undetected."
Fujirebio is in the process of initiating the clinical development and commercialization of the mesothelioma test. Dr. Daniel O'Shannessy, FDI's Chief Scientific Officer, says that this new assay "will provide, for the very first time, a highly effective way of tracking d
'"/>
Contact: Rich Murphy
rmurphy@pnri.org
206-726-1200
Pacific Northwest Research Institute
13-Nov-2003